c-LEcta, a Leipzig, Germany-based biotechnology company focused on enzyme engineering and applications in regulated markets like food and pharma, closed a financing round of undisclosed amount.
Backers included Capricorn Venture Partners and investment company bm|t.
The company intends to use the funds to continue to scale operations and food ingredients manufacturing capacity to commercial production.
Led by Founder and CEO Dr. Marc Struhalla, c-LEcta is a biotechnology company with focus on enzyme engineering and application in regulated markets like food and pharma. The company has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. It currently employs approximately 60 people.